Life Sciences Transactions

We represent life sciences clients in the full array of mission-critical transactions, including licensings, strategic collaborations, financings, joint ventures, and mergers and acquisitions. Our clients range from startups to emerging biotechs and established global pharmaceutical companies, as well as venture capital, private equity, and investment banking firms focused on the life sciences industry.

Comprehensive Life Sciences Transactions

Our life sciences transactions team helps clients build, negotiate, and implement essential strategic partnerships with other pharmaceutical, biotech, and diagnostic companies, as well as the academic, government, and nonprofit sectors. We leverage our industry-specific experience to advise clients on transactions to research, develop, and commercialize products and technologies.

Services Across the Entire Transaction Lifecycle

Our life sciences transaction experience includes early-stage licensing and research deals, strategic development and commercialization collaborations, mergers and acquisitions (M&A), and public offerings and other exit events. In the course of structuring and negotiating transactions, we offer an expansive range of legal services covering intellectual property, US Food and Drug Administration–related issues, antitrust, tax, and US and global governmental regulation. We assist clients with operational matters such as supply, distribution, clinical trial, and co-promotion agreements, as well as equity investment agreements. We also represent academic institutions and industry partners in licensing technology and sponsored research programs.

Learn more about our Life Sciences services.

Life Sciences M&A, Private Equity, and Venture Investments

Our lawyers represent life sciences companies on product-related acquisitions and divestitures as well as public and private M&A. We handle transactions of varying sizes and of all different types, including asset and stock purchases, tender offers, proxy contests, restructurings, leveraged buyouts, and going-private transactions. We also represent investment banks and commercial banks, venture capital firms, private equity firms, institutional lenders, independent director committees, and management groups in their M&A-related matters.

In addition, our team advises private equity and venture capital firms, as well as nonprofits, on fund formation and other investment vehicles, and we counsel pharmaceutical clients on their participation in these funds.

Learn more about our Mergers & Acquisitions, Private Equity, and Emerging Business & Technology services.

Who We Serve

Our clients run the gamut from startups and emerging companies to household names around the world, including:

  • 17 of the top 20 pharmaceutical companies
  • 8 of the top 20 biotechnology companies
  • 13 of the top 20 medical device companies

Accolades & Honors

  • Ranked, Life Sciences & Pharmaceutical Sector (International & Cross-Border), USA, Chambers Global (2020–2022)
  • Ranked, Life Sciences, Nationwide, Chambers USA (2014–2023)
  • Recommended, Healthcare: Life Sciences, The Legal 500 US (2014–2023)
  • Recommended, Licensing and Collaboration, LMG Life Sciences (2021, 2022)